We have investigated the molecular mechanism whereby 1,25-dihydroxyvitamin D 3 [1,25(OH)2D3] inhibits adipogenesis in vitro. 1,25(OH)2D3 blocks 3T3-L1 cell differentiation into adipocytes in a dose-dependent manner; however, the inhibition is ineffective 24 -48 h after the differentiation is initiated, suggesting that 1,25(OH) 2D3 inhibits only the early events of the adipogenic program. Treatment of 3T3-L1 cells with 1,25(OH) 2D3 does not block the mitotic clonal expansion or C/EBP␤ induction; rather, 1,25(OH) 2D3 blocks the expression of C/EBP␣, peroxisome proliferator-activated receptor-␥ (PPAR␥), sterol regulatory element-binding protein-1, and other downstream adipocyte markers. The inhibition by 1,25(OH) 2D3 is reversible, since removal of 1,25(OH) 2D3 from the medium restores the adipogenic process with only a temporal delay. Interestingly, although the vitamin D receptor (VDR) protein is barely detectable in 3T3-L1 preadipocytes, its levels are dramatically increased during the early phase of adipogenesis, peaking at 4 -8 h and subsiding afterward throughout the rest of the differentiation program; 1,25(OH) 2D3 treatment appears to stabilize the VDR protein levels. Consistently, adenovirus-mediated overexpression of human (h) VDR in 3T3-L1 cells completely blocks the adipogenic program, confirming that VDR is inhibitory. Inhibition of adipocyte differentiation by 1,25(OH) 2D3 is ameliorated by troglitazone, a specific PPAR␥ antagonist; conversely, hVDR partially suppresses the transacting activity of PPAR␥ but not of C/EBP␤ or C/EBP␣. Moreover, 1,25(OH) 2D3 markedly suppresses C/EBP␣ and PPAR␥ mRNA levels in mouse epididymal fat tissue culture. Taken together, these data indicate that the blockade of 3T3-L1 cell differentiation by 1,25(OH) 2D3 occurs at the postclonal expansion stages and involves direct suppression of C/EBP␣ and PPAR␥ upregulation, antagonization of PPAR␥ activity, and stabilization of the inhibitory VDR protein.
Molecular mechanism of 1,25-dihydroxyvitamin D 3 inhibition of adipogenesis in 3T3-L1 cells
A LARGE BODY OF LITERATURE has demonstrated that adipocyte differentiation follows a well-defined program. Much of our current understanding of the molecular regulation of adipogenesis comes from in vitro studies of preadipocyte cell lines such as 3T3-L1, 3T3-F442A, and Ob1771 (12) (13) (14) 32) . According to the current model, the adipogenic program involves several sequential stages over a period of 4 -7 days (36, 38) . Under the induction of prodifferentiative agents, including insulin, glucocorticoids, and phosphodiesterase inhibitor, growth-arrested cells undergo one or two rounds of cell division known as mitotic clonal expansion, which is accompanied by the induction of C/EBP␤ and C/EBP␦. These earliest events are followed by increased expression of C/EBP␣ and PPAR␥, the central transcriptional regulators of adipogenesis, which drive adipocyte-specific gene expression. Subsequently, in the final stage, the cells are terminally differentiated into mature adipocytes. These differentiated cells now express markers characteristic of adipocyte phenotype such as fatty acid synthase (FAS), lipoprotein lipase (LPL), acetyl-CoA carboxylase, GLUT4, and fatty acid-binding protein aP2, along with massive accumulation of triglyceride inside the cells.
1,25-Dihydroxyvitamin D 3 [1, 25 (OH) 2 D 3 ], the most active form of vitamin D metabolites, is an endocrine hormone that plays multiple physiological roles (46) . This secosteroid hormone is known to be critical for the homeostasis of calcium and phosphate (27, 52) . It also regulates sulfate transport (5), the renin-angiotensin system (26) , the immune system (29) , and normal organ development such as the mammary gland and skeletal muscle (9, 53) . 1,25(OH) 2 D 3 has previously been shown to regulate adipocyte differentiation; however, somewhat conflicting results have been reported regarding the role of vitamin D in adipogenesis. In early reports, vitamin D receptor (VDR)-like molecule was detected in 3T3-L1 cells (39) , and 1,25(OH) 2 D 3 was shown to pose an inhibitory effect on 3T3-L1 differentiation on the basis of its inhibition of glycerophosphate dehydrogenase activity and triglyceride content (21, 39) or its ability to counter the stimulatory effect of a peroxisome proliferator-activated receptor-␥ (PPAR␥) ligand on 3T3-L1 differentiation (18) . 1,25(OH) 2 D 3 was also able to inhibit adipocyte differentiation in mouse bone marrow stromal cells (22) . On the other hand, 1,25(OH) 2 D 3 was shown to promote adipocyte differentiation in primary rat calvaria cells (4) and rat bone marrow stromal cells (2) and to stimulate LPL expression in 3T3-L1 cells (35, 49) . Other recent studies demonstrated that 1,25(OH) 2 D 3 can stimulate FAS and suppress uncoupling protein 2 and leptin production in primary human adipocytes and adipose organ cultures (30, 41, 42) .
Despite the conflicting conclusions reported in the literature, few studies have been carried out to systematically investigate the molecular mechanism underlying the effect of vitamin D on adipogenesis. Given the importance of the adipose tissue in the development of human diseases such as metabolic syndrome, delineation of the molecular events involved in vitamin D regulation of adipogenesis has become quite necessary. Here we report a systematic study aimed at understanding the molecular mechanism whereby 1,25(OH) 2 D 3 inhibits adipogenesis in the 3T3-L1 cell model. Our data suggest that vitamin D acts on multiple targets to block adipocyte differentiation in vitro.
EXPERIMENTAL PROCEDURES
Cell culture and treatment. 3T3-L1 cells (ATCC, Manassas, VA) were routinely cultured in growth medium (GM) consisting of DMEM supplemented with 10% FBS (Hyclone, Logan, UT) and 2 mM glutamine. The cells were differentiated according to a well-established protocol described previously (44) . Briefly, for differentiation, 3T3-L1 cells were cultured in GM to full confluency. Two days after confluency (referred to as day 0), the cells were switched to differentiation media (DM) consisting of DMEM supplemented with 10% FBS, 1 g/ml insulin, 0.25 M dexamethasone, and 0.5 mM isobutyl methylxanthine and cultured for 3 days. Next, the cells were maintained in DM but containing only 1 g/ml insulin, and the medium was changed every 2-3 days. The cells normally differentiated into mature adipocytes on day 7 or 8. Depending on the purpose of the experiment, 1,25(OH) 2D3 or ethanol (vehicle) was added to the DM at the indicated doses or at different times. In other experiments, troglitazone at indicated concentrations was also added to the cell culture system. The cells were harvested at indicated times during differentiation for RNA or protein extraction or stained with Oil Red O (Sigma, St. Louis, MO) according to the procedure described previously (40) . In thymidine incorporation assays, 1 Ci/ml of [ 3 H]thymidine was added to the culture after the DM switch, and the amount of [ 3 H]thymidine incorporated in the cells was determined with a scintillation counter after 48 or 72 h as described previously (50) .
Recombinant adenovirus and infection. Recombinant adenovirus harboring human (h) VDR cDNA was generated using the AdEasy system according to the method described previously (17) . The recombinant virus, Ad-hVDR, expresses the full-length hVDR protein. Ad-hVDR and Ad-GFP, the empty vector, were used to infect 3T3-L1 cells at confluency (day Ϫ2) at multiplicity of infection of ϳ10 4 . Next, at day 0, the infected cells were switched to the DM to initiate cell differentiation according to the standard protocol.
Isolation of mouse embryonic fibroblast. Mouse embryonic fibroblasts (MEF) were isolated from embryonic day 13.5 embryos generated from VDR ϩ/Ϫ ϫ VDR ϩ/Ϫ mouse breeding (27) . Briefly, the embryos were harvested and placed in PBS to remove the internal organs, head, and four limbs. The remaining embryo body was individually minced and then digested with 0.5% trypsin and 10 mM EDTA for 0.5 h at 37°C. The digested materials were gently pipetted to a single cell suspension. The cells were cultured in DMEM supplemented with 10% FBS and used after three to four passages. Cells from each embryo were genotyped by PCR using genomic DNA isolated form the cells. VDR ϩ/ϩ and VDR Ϫ/Ϫ MEFs were differentiated according to the standard protocol described above.
Northern blot. Total cellular RNA was extracted using TRIzol reagents (Invitrogen, Grand Island, NY) according to instructions provided by the supplier. Northern blot analysis was carried out as described previously (25) . Briefly, total RNAs (20 g/lane) were separated on 1% agarose gels containing 0.6 M formaldehyde and transferred to Nylon membranes that were cross-linked in an ultraviolet cross-linker. Hybridization was carried out at 65°C in the hybridization buffer described by Church and Gilbert (7) with cDNA probe labeled with [ 32 P]dATP using the Prime-a-Gene Labeling System (Promega, Madison, WI). After hybridization and being washed, the membranes were exposed to X-ray films at Ϫ80°C for autoradiography to visualize the mRNA transcript. The membranes were stripped and rehybridized with 32 P-labeled 36B4 cDNA probe for internal loading control.
Western blot. Western blot analyses were carried out as described previously (25) . Briefly, cells were lysed with the Laemmli buffer (23), and cell lysates were separated by SDS-PAGE. The separated proteins were then electroblotted on Immobilon-P membranes. The membrane blots were first probed with a primary antibody. After incubation with horseradish peroxidase-conjugated second antibody, autoradiograms were prepared using the enhanced chemiluminescent system (Amersham, Piscataway, NJ) to visualize the protein antigen.
Cell transfection and luciferase reporter assays. 3T3-L1 cells were cultured in DMEM supplemented with 10% FBS. The cells, at ϳ60 -80% confluency, were cotransfected in duplicate with C/EBPREx3-tk-Luc or PPREx3-tk-Luc reporter plasmid (15) and other cDNA expression plasmids detailed in each experiment, using Lipofectamine reagent (Invitrogen) according to the instructions provided by the manufacturer. Cell luciferase activity was assayed after 24 -48 h using the Firefly Luciferase Assay System (Promega) or Renilla Luciferase assay kit (Biotium, Hayward, CA). To normalize the transfection efficiency, a pCMV-␤-gal plasmid was included in each transfection, and luciferase activity was normalized to ␤-galatosidase activity in each transfection. The ␤-galactosidase activity was determined by using the Gel-Screen Chemiluminescent Reporter System (Tropix, Bedford, MA).
Adipose tissue culture. Epididymal fat pads were dissected immediately after mice were killed and placed in cold PBS (pH 7.2) kept on ice. The fat pads were rinsed two times with cold PBS, transferred to cold DMEM containing 2% FBS and 1 g/ml insulin, and cut with sterile scissors into small pieces. The fat pieces were cultured in six-well plates at 37°C and 5% CO 2 in the presence or absence of 10 Ϫ8 M of 1,25(OH)2D3, and total RNAs were extracted at 24, 36, and 48 h. The RNAs were subject to Northern blot analyses. Ϫ8 M (Fig. 1A) . The expression of gene transcripts known to be associated with early and late stages of adipocyte differentiation, including C/EBP␣, PPAR␥, LPL, and aP2, was also blocked by 1,25(OH) 2 D 3 in a dose-dependent fashion ( Fig.  2A ). Other genes, such as the sterol regulatory element-binding protein (SREBP)-1 and FAS, which were upregulated when the cells were turned to adipocytes, were also suppressed dose dependently by 1,25(OH) 2 D 3 ( Fig. 2C) .
RESULTS

Inhibition of adipocyte differentiation by 1,25(OH)
Interestingly, however, when 1,25(OH) 2 D 3 (10 Ϫ8 M) was added to the DM 48 h after the adipogenic program was initiated, adipocyte differentiation could no longer be blocked (Fig. 1B) . Consistently, the expression of the adipocyte differentiation markers, including C/EBP␣, PPAR␥, LPL, and aP2, were no longer inhibited by 1,25(OH) 2 D 3 after 48 h (Fig. 2B ). These data clearly indicate that the window in which 1,25(OH) 2 D 3 can effectively inhibit 3T3-L1 adipogenesis is within the first 48 h after the differentiation program is initiated.
Blockade of adipogenesis by 1,25(OH) 2 D 3 occurs after clonal expansion and C/EBP␤ induction.
It is well known that, within a few hours after the adipogenic program is initiated, the cells undergo one or two rounds of mitotic clonal expansion in the first 48 h, which is accompanied by an upregulation of C/EBP␤ and C/EBP␦ expression (48) . To investigate whether 1,25(OH) 2 D 3 affected these early events, 3T3-L1 cells were treated with 1,25(OH) 2 D 3 (10 Ϫ8 M) at hour 0, and the cells were analyzed at different times after the differentiation process was initiated. As shown in Fig. 3 , 4 h after 3T3-L1 cells were switched to DM, C/EBP␤ expression was markedly upregulated, whereas PPAR␥ upregulation was not detected until after 24 h. Treatment with 1,25(OH) 2 D 3 completely blocked PPAR␥ expression but had no effect on C/EBP␤ upregulation (Fig. 3A) . Because C/EBP␤ is required for the induction of the downstream PPAR␥ and C/EBP␣ (47, 51) , it is possible that 1,25(OH) 2 D 3 indirectly inhibits C/EBP␣ and PPAR␥ mRNA expression by inhibiting the transacting activity of C/EBP␤ as in the case of retinoic acid inhibition of 3T3-L1 differentiation (40) . To test this possibility, preadipocyte 3T3-L1 cells were transfected with a C/EBPREx3-tk-Luc reporter plasmid in GM. Next, the cells were switched to DM, and luciferase activity was determined after 16 h when C/EBP␣ and PPAR␥ remained uninduced (Fig. 3A) . As shown in Fig. 3B , the switch to DM led to an approximately twofold increase in luciferase activity resulting from C/EBP␤ induction, and this activity increase was not affected in the presence of 1,25(OH) 2 D 3 (Fig. 3B) . Therefore, 1,25(OH) 2 D 3 affects neither the induction of the C/EBP␤ transcript nor its transacting activity.
Consistent with these observations, 1,25(OH) 2 D 3 treatment does not affect the mitotic clonal expansion either. As shown in Fig. 4 , the cell number almost doubled in 24 h after switching to the DM, and continued to increase at 72 h, regardless of 1,25(OH) 2 D 3 treatment (Fig. 4A) ; similarly, 1,25(OH) 2 D 3 treatment had no effect on the incorporation of [ 3 H]thymidine into DNA stimulated by the DM (Fig. 4B) Given the importance of VDR, the level of VDR protein in 3T3-L1 cells was determined at different stages of the adipogenesis process. As shown in Fig. 7 , VDR protein was barely detectable in 3T3-L1 preadipocytes grown in GM; however, when the cells were switched to DM, VDR protein levels were drastically increased and peaked within 4 -8 h, which gradually declined afterward along the progression of the differentiation process so that the VDR protein became barely detectable in mature adipocytes at day 8 (Fig. 7A) . On the other hand, the protein level of retinoid X receptor (RXR)-␣ was gradually increased after differentiation (Fig. 7B) . Interestingly, in the presence of 1,25(OH) 2 D 3 , VDR protein, particularly the upper slow-moving isoform, was markedly increased and stabilized at the late stages of differentiation (Fig. 7A) , whereas RXR␣ levels appeared to be repressed in the first 2 days (24 -39 h; Fig. 7B ). As a control, the level of extracellular signal-regulated kinase, a protein known to be important for 3T3-L1 differentiation (34) , was unaltered in the presence or absence of 1,25(OH) 2 D 3 (Fig. 7C) .
To confirm the inhibitory activity of VDR in adipogenesis, hVDR was overexpressed in 3T3-L1 fibroblasts by infection with recombinant adenovirus harboring the full-length hVDR cDNA (Fig. 8A) . When the hVDR-expressing 3T3-L1 cells were cultured in the DM, they ceased to differentiate into adipocytes, even in the absence of 1,25(OH) 2 address this question, adipose tissues isolated directly from mice were treated with 1,25(OH) 2 D 3 ex vivo for up to 2 days, and this treatment clearly decreased PPAR␥ and C/EBP␣ mRNA levels in a time-dependent manner (Fig. 9, A and B) . Because changes in the differentiation paradigm do not occur in the adipose tissues, this result suggests that 1,25(OH) 2 D 3 inhibition of PPAR␥ and C/EBP␣ expression in 3T3-L1 cells is a primary, direct event.
1,25(OH) 2 D 3 antagonizes the transacting activity of PPAR␥.
Troglitazone is a PPAR␥ angonist and was able to induce 3T3-L1 cell differentiation in GM (Fig. 10A) . Moreover, troglitazone was able to ameliorate the inhibition of adipocyte differentiation by 1,25(OH) 2 D 3 or retinoic acid, as reflected by the higher LPL levels in the presence of troglitazone (Fig.  10B) . Retinoic acid is a known inhibitor of 3T3-L1 cell differentiation (40) . Given that both VDR and PPAR␥ share the same heterodimeric partner RXR and that RXR levels are considerably lower in the early phase of 3T3-L1 cell differentiation (Fig. 7B) , we speculated that VDR may directly suppress the transacting activity of PPAR␥ by sequestering the limited amount of RXR in 3T3-L1 cells. To test this possibility, 3T3-L1 cells were transfected with a PPREx3-tk-Luc reporter plasmid. When the cells were cotransfected with PPAR␥ cDNA, the luciferase activity was increased by two-to threefold, as expected, and this induction was partially inhibited by 1,25(OH) 2 D 3 treatment (Fig. 10C) . Cotransfection of hVDR cDNA inhibited the increase in luciferase activity induced by PPAR␥, even in the absence of 1,25(OH) 2 D 3 ; hVDR cDNA cotransfection also reduced the basal PPRE-luciferase activity (Fig. 10C) . These observations were consistent with the data showing that adenoviral overexpression of hVDR inhibited 3T3-L1 cell differentiation in the absence of 1,25(OH) 2 D 3 ( Fig. 8B) , suggesting that RXR may be a limiting factor in 3T3-L1 cells. To further test the possibility, a RXR␣ expression plasmid was included in the cotransfection experiment. RXR significantly increased the transacting activity of PPAR␥ (Fig. 10D) . In the presence of RXR, hVDR was no longer able to inhibit the transacting activity of PPAR␥ regardless of the presence and absence of 1,25(OH) 2 D 3 (Fig. 10D) . We also found that 1,25(OH) 2 D 3 treatment or cotransfection with hVDR had little effect on the transacting activity of C/EBP␣ (data not shown). These data suggest that VDR may specifically antagonize the transacting activity of PPAR␥ during 3T3-L1 cell differentiation.
DISCUSSION
Although 1,25(OH) 2 D 3 has been reported to inhibit adipocyte differentiation in 3T3-L1 cells for more than a decade, (24), we speculate that 1,25(OH) 2 D 3 inhibits adipocyte differentiation by acting on multiple molecular targets, and the mechanism of inhibition is complex.
Upon initiation of the adipogenic program, preadipocytes undergo mitotic clonal expansion that is composed of one or two rounds of cell division. Interestingly, although 1,25(OH) 2 D 3 is well known to have potent antiproliferative activity and inhibits cell division in many cell types, including normal and malignant cells, it does not affect the clonal expansion in 3T3-L1 cells. C/EBP␤ upregulation is a very early event that is required for the mitotic clonal expansion (47) and mediates the downstream upregulation of PPAR␥ and C/EBP␣ expression (51) . Interestingly, a recent study shows that 1,25(OH) 2 D 3 stimulates C/EBP␤ expression in kidney cells (8) . However, we show here that 1,25(OH) 2 D 3 has no effect on the upregulation of C/EBP␤ mRNA expression in the early stage of adipocyte differentiation, nor does it affect the transacting activity of C/EBP␤ protein. Therefore, 1,25(OH) 2 D 3 suppression of the upregulation of C/EBP␣ and PPAR␥ is independent of C/EBP␤. This is different from retinoic acid inhibition of adipogenesis in 3T3-L1 cells, which inhibits C/EBP␤ transactivating activity (40) .
C/EBP␣ and PPAR␥ are the central transcriptional regulators of adipogenesis since they are required for the syntheses of many adipocyte functional proteins. C/EBP␣ and/or PPAR␥ have been reported to be the target of other adipogenic inhibitors such as calcineurin and Kruppel-like factor KLF2 (3, 31) . In 3T3-L1 cells, 1,25(OH) 2 D 3 appears to directly suppress the induction of C/EBP␣ and PPAR␥ and antagonize the transacting activity of PPAR␥. Although it is possible that the blocking of C/EBP␣ and PPAR␥ by 1,25(OH) 2 D 3 can be secondary to its inhibition of 3T3-L1 cell differentiation, the fact that 1,25(OH) 2 D 3 also suppresses C/EBP␣ and PPAR␥ expression in mature adipose tissues argues against this possibility and supports a direct repression because the concern of adipocyte differentiation is not an issue for the epididymal fat. Therefore, inhibition of C/EBP␣ and PPAR␥ by 1,25(OH) 2 D 3 is likely a cause, but not a consequence, of the in vitro adipogenic inhibition. This conclusion is consistent with the observation that 1,25(OH) 2 D 3 can no longer block adipogenesis 48 h after the adipogenic program is initiated, because at this time the upregulation of C/EBP␣ and PPAR␥ has already taken place. Clearly, targeting C/EBP␣ and PPAR␥ is key to vitamin D's effect on adipogenesis. Taken together with the evidence that 1,25(OH) 2 D 3 does not affect C/EBP␤, the upstream regulator of C/EBP␣ and PPAR␥, we conclude that 1,25(OH) 2 D 3 blocks 3T3-L1 cell differentiation by directly suppressing the upregulation of C/EBP␣ and PPAR␥. Given the important role of C/EBP␣ and PPAR␥ in adipogenesis, targeting C/EBP␣ and PPAR␥ may likely be the major mechanism of vitamin D's inhibitory actions. More studies are needed to investigate the exact molecular mechanism underlying the suppression of these two genes by vitamin D.
The data from the cotransfection studies suggest that 1,25(OH) 2 D 3 also counters the transacting activity of PPAR␥. This is likely achieved by competing for the limited amount of RXR through VDR, since RXR is the common heterodimeric partner of both VDR and PPAR␥. Because the levels of RXR in 3T3-L1 cells are very low in the early stages of differentiation (relative to the late stages; Fig. 7B ), VDR, once activated by 1,25(OH) 2 D 3 binding, may sequester RXR from PPAR␥ in the early phase of adipogenesis, when the activity of PPAR␥ is crucial to advance the differentiation program. In the case of VDR overexpression, the large quantity of VDR in the cells may sequester RXR without ligand activation, and overexpression of RXR can apparently prevent the sequestering effect of VDR.
It is very intriguing that the levels of VDR protein change during the course of adipocyte differentiation. Although the VDR protein level is barely detectable in the preadipocyte 3T3-L1 cells, it drastically increased within 4 -8 h of the initiation of adipogenesis, which is followed by a gradual decline with the progression of differentiation. A similar VDR mRNA profile has also been reported in two other recent studies in which 3T3-L1 adipocyte differentiation was investigated by microarray analysis (6, 11) . It is worth pointing out that the maximal induction of VDR takes place at approximately the same time as C/EBP␤ induction and is much earlier than the upregulation of C/EBP␣ and PPAR␥. Interestingly, ecotopic expression of hVDR by adenovirus completely blocks adipogenesis even in the absence of the ligand, 1,25(OH) 2 D 3 , suggesting that VDR protein itself is inhibitory to adipogenesis. One possible mechanism is the sequestering of RXR by the excessive amount of VDR inside the cells. Therefore, naturally, the VDR level needs to be declined for the adipogenic process to proceed, but why it needs to be dramatically increased in the early phase remains an interesting question. Clearly, the biological significance of the VDR profile during adipogenesis requires further investigation.
In the presence of 1,25(OH) 2 D 3 , VDR protein in 3T3-L1 cells appears to be more stabilized, particularly in the late stages of the adipogenic program (Fig. 7A) . In fact, stabilization of the VDR protein by 1,25(OH) 2 D 3 has been reported in other cells (1) . Therefore, because VDR is inhibitory, another possible mechanism that 1,25(OH) 2 D 3 uses to inhibit adipocyte differentiation is to prevent the decline of the VDR protein concentration in the late stages. What is particularly intriguing is that 1,25(OH) 2 D 3 appears to stabilize the slower-moving VDR species more (Fig. 7A) . The VDR band of slower mobility may represent phosphorylated VDR (19, 20) or the VDR variant generated from the alternatively spliced first exon of the VDR gene that was identified recently (45) . It will be interesting to ascertain the identity of this VDR isoform in future studies.
As an endocrine hormone, the in vivo effect of vitamin D on adipocytes/adipose tissue remains unclear, and whether the vitamin D status has any connection with human obesity is controversial (28, 33, 43) . Given the link of obesity with metabolic syndrome, an increasingly epidemic problem char-acterized by insulin resistance and dyslipidemia (10) , the role of the vitamin D endocrine system in adipocyte biology is definitely worth further investigations.
